MIG
(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Find entries where: MIG
is present as a standalone ligand in 4 entries
Chemical Component Summary | |
---|---|
Name | (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol |
Synonyms | Miglitol |
Identifiers | (1R,2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol |
Formula | C8 H17 N O5 |
Molecular Weight | 207.224 |
Type | NON-POLYMER |
Isomeric SMILES | C1[C@@H]([C@H]([C@@H]([C@H]([N@@]1CCO)CO)O)O)O |
InChI | InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1 |
InChIKey | IBAQFPQHRJAVAV-ULAWRXDQSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 31 |
Chiral Atom Count | 4 |
Bond Count | 31 |
Aromatic Bond Count | 0 |
Drug Info: DrugBank
DrugBank ID | DB00491 |
---|---|
Name | Miglitol |
Groups | approved |
Description | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. |
Synonyms |
|
Brand Names |
|
Indication | For use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone. |
Categories |
|
ATC-Code | A10BF02 |
CAS number | 72432-03-2 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Lysosomal alpha-glucosidase | MGVRHPPCSHRLLAVCALVSLATAALLGHILLHDFLLVPRELSGSSPVLE... | unknown | antagonist |
Neutral alpha-glucosidase AB | MAAVAAVAARRRRSWASLVLAFLGVCLGITLAVDRSNFKTCEESSFCKRQ... | unknown | antagonist |
Neutral alpha-glucosidase C | MEAAVKEEISLEDEAVDKNIFRDCNKIAFYRRQKQWLSKKSTYQALLDSV... | unknown | antagonist |
Maltase-glucoamylase, intestinal | MARKKLKKFTTLEIVLSVLLLVLFIISIVLIVLLAKESLKSTAPDPGTTG... | unknown | antagonist,inhibitor |
Pancreatic alpha-amylase | MKFFLLLFTIGFCWAQYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPK... | unknown | inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1561 |
PubChem | 441314 |
ChEMBL | CHEMBL1561 |
ChEBI | CHEBI:6935 |